立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

生脉注射液防治放射性心脏损伤疗效观察

目的：观察生脉注射液对放射心脏损伤的防治疗效．方法：确诊为胸部恶性肿瘤者71例，随机分为治疗组和对照组．治疗组37例放疗全程应用生脉注射液40—60ml＋5％葡萄糖注射液250ml静脉点滴，每天一次．对照组34例放疗开始后两周应用强的松40mg每天一次，晨服，2周为1疗程．两组放疗累积生物剂量至DT60—70Gy．结果：放疗后比较生脉注射液组心电图异常及酶学变化明显低于对照组（P〈0．05），且放疗前后比较生脉组差异无显著性而对照组差异有显著性（P〈0．05）．心脏形态改变生脉组与对照组比较差异有显著性（P〈0．05）．结论：生脉注射液可降低心脏的放射损伤反应，安全无明显毒副反应，可作胸部肿瘤放疗时为防治放射性心脏损伤的一种方法用于临床．     

核素显像鉴别甲状腺结节良恶性的临床价值分析

目的分析并评价99mTc-MIBI亲肿瘤显像在判定甲状腺结节良恶性中的应用价值。方法对本组489例甲状腺结节患者实施手术治疗以及病理检查,并对病理报告结果与99mTc-MIBI甲状腺亲肿瘤显像结果的相符情况进行分析。结果 99mTc-MIBI亲肿瘤显像的假阳性率、假阴性率分别为19.11%和39.64%;阳性与阴性预测值分别为46.96%和85.64%;其准确度、特异度以及敏感度分别为76.36%、80.86%和60.32%;阳性与阴性似然比分别为3.12和0.47;其甲状腺恶性结节发病率为21.91%。结论甲状腺99mTc-MIBI亲肿瘤显像在鉴别甲状腺良恶性方面具有较好的参考价值。     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

99mTc-MDP全身骨显像对骨转移瘤的诊断价值

目的 探讨99 mTc-MDP(99 m锝-亚甲基二膦酸盐)全身骨显像对骨转移瘤的诊断价值.方法 常规采用99 mTC-MDP为显像剂,对临床诊断为肺癌、乳腺癌、前列腺癌的230例患者进行核素全身骨显像.结果 230例癌症患者核素骨显像示骨转移者136例,阳性率58.3%,其中肺癌100例,骨转移68例,阳性率68%;乳腺癌100例,骨转移49例,阳性率49%;前列腺癌30例,骨转移19例,阳性率63%.结论 肺、乳腺、前列腺癌患者核素骨显像对病程分期、治疗方案选择及预后评估均有重要的临床参考价值.     

99mTc—MIBI骨显像对四肢骨单发浓集灶的诊断价值

目的：探讨99mTc—MIBI骨显像对四肢骨单发浓集灶的诊断价值。方法：对99mTc—MDP骨显像发现四肢骨单发浓集灶并经病理学确诊患者27例,行99mTc—MIBI骨显像,总结其对四肢骨单发浓集灶的判定结果。结果：99mTc—MIBI骨显像在全部病例的显像阳性率为63．0％,在四肢骨单发骨转移的显像阳性率为76．2％,在良性病变的显像阳性率为16．7％,骨转移与良性病灶显像结果比较有差异性（X2=5．51,P〈0．05）。结论：99mTc—MIBI骨显像在四肢骨骨转移诊断方面较99mTc—MDP骨显像具有敏感性高、假阳性率低的特点,可作为99mTc—MDP骨显像的有益补充用于四肢骨单发骨转移的早期诊断。     

龙血竭治疗急性放射性皮肤损伤的临床疗效观察

笔者应用龙血竭治疗急性放射性皮肤损伤取得满意的临床疗效,现报道如下. 一、资料与方法 1.临床资料;2000年1月至2008年6月在平顶山市第二人民医院接受放射治疗中出现2-4级急性放射性皮肤损伤患者246例,其中采用龙血竭治疗的132例为治疗组,采用生理盐水+庆大霉素+地塞米松治疗的114例为对照组.     

89SrCl2联合放疗治疗多发骨转移癌的疗效

目的探讨89SrCl2联合放疗治疗多发骨转移癌的临床疗效。方法将67例多发骨转移癌患者随机分为2组：对照组34例采用89SrCl2治疗,观察组33例采用89SrCl2联合放射治疗。结果对照组与观察组止痛疗效完全缓解率、显效率分别为20．6％、58．9％和51．5％、90．9％,2组比较差异均有统计学意义（P〈0．01）,对转移灶疗效2组显效率相比差异有统计学意义（8．8％vs15．2％,P〈O．05）。结论89SrCl2治疗多发骨转移癌疗效肯定,与放疗联合疗效更佳。     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

目的 分析X刀分次立体定向放疗(FSRT)联合全脑照射(WBRT)治疗脑转移瘤疗效。方法 回顾性分析51例脑转移瘤FSRT+WBRT和35例脑转移瘤单纯WBRT的结果,比较分析两者有效率、生存率的差异。结果 FSRT+WBRT、WBRT组完全缓解率分别为49%、26%(P<0.05),中位生存期分别为(11.0±1.5)、(6.5±0.5)个月(P<0.05),18个月生存率分别为24%、9%(P<0.05)。两组有效率(8%、71%,P>0.05)和6、12个月生存率(63%、41%,51%、23%,P>0.05)相似。 结论 X刀FSRT联合WBRT治疗脑转移瘤损伤小、安全、延长生存期,疗效优于单纯全颅放疗。     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.